Statement: One of the cohorts in the primary trial had more than 5% of patients experiencing side effects.
Primary_evidence: Adverse Events 1:   Total: 66/1748 (3.78%)   Febrile neutropenia 2/1748 (0.11%)   Cardiac disorders - Other, specify 3/1748 (0.17%)   Conduction disorder 0/1748 (0.00%)   Myocardial infarction 0/1748 (0.00%)   Ventricular arrhythmia 1/1748 (0.06%)   Left ventricular systolic dysfunction 0/1748 (0.00%)   Colitis 1/1748 (0.06%)   Diarrhea 0/1748 (0.00%)   Duodenal ulcer 0/1748 (0.00%) Adverse Events 2:   Total: 43/1748 (2.46%)   Febrile neutropenia 1/1748 (0.06%)   Cardiac disorders - Other, specify 1/1748 (0.06%)   Conduction disorder 0/1748 (0.00%)   Myocardial infarction 1/1748 (0.06%)   Ventricular arrhythmia 0/1748 (0.00%)   Left ventricular systolic dysfunction 1/1748 (0.06%)   Colitis 1/1748 (0.06%)   Diarrhea 1/1748 (0.06%)   Duodenal ulcer 1/1748 (0.06%)